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The B-cell leukemia/lymphoma 11B (BCL11B) gene is a member of the BCL family which plays a crucial role in the
development, proliferation, differentiation and subsequent survival of T cells. BCL11B gene alterations are related to
malignant T cell transformation that occurs in hematological malignancies. Remarkably, the BCL11B gene is
responsible for the regulation of the apoptotic process and cell proliferation. This review summarizes current data
and knowledge concerning the alteration of BCL11B in hematological malignancies and its role as a potential target
for therapies directed against T cell malignancies.
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The structure of BCL11B
The BCL11B gene
B-cell leukemia/lymphoma 11B (BCL11B) was first
described by Ed Satterwhite in 2001. The BCL11B gene
is located on mouse chromosome 12 (52.0 cM) and
human chromosome 14 (q32.1). Murine BCL11B shows
88% identity to the human BCL11B at nucleotide level.
It has been successfully demonstrated that BCL11B ex-
pression begins in the early double negative 1 (DN 1)
cell stage in the thymus, and is primarily expressed in T
cells, thymocytes and brain tissue [1]. This gene was ori-
ginally referred to as RIT1 (radiation-induced tumor
suppressor gene 1) because BCL11B was isolated by
scanning γ-ray-induced mouse thymic lymphomas for
the loss of specific chromosomal DNA [2]. BCL11B is
also known as CTIP2 (COUP-TF-interacting protein 2)
because it was isolated for its interaction with the or-
phan nuclear receptor chicken ovalbumin upstream pro-
moter transcription factor (COUP-TF) [3]. The BCL11B
gene consists of 4 exons, and two alternatively spliced
transcript variants, which encode distinct isoforms pos-
sessing or lacking exon 3, have been reported (Figure 1)
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BCL11B belongs to the Kruppel-like C2H2 type zinc fin-
ger transcription factor family that contains 6 C2H2 zinc
fingers and proline-rich and acidic regions with 95%
identity in their zinc finger domains [4]. BCL11B
encodes two different isoforms consisting of 823 and
894 aa in humans (Figure 1). These structures include
DNA binding and protein interacting regions. The long
exon 4 comprises the 6 zinc-finger domains, and the 2nd
and 3rd domains are responsible for DNA binding. Apart
from the DNA binding region, BCL11B possesses
domains responsible for interaction with proteins and
protein complexes [5].BCL11B biological functions
The specific functions of this gene have yet to be deter-
mined. The number of BCL11B functional studies have
recently been on the rise.Transcriptional regulator
As a transcription factor, BCL11B may be a bi-functional
transcriptional regulator that acts as a repressor and
transactivator [6]. BCL11B interacts with COUP-TF [3]
and nucleosome remodeling and histone deacetylation
complex (NuRD) [7], rendering it a potent transcrip-
tional repressor. Genes encoding the cyclin-dependent
kinase inhibitors p21/Cip2/Waf1 and p57/Kip2 are tran-
scriptionally suppressed by BCL11B [8,9]. BCL11B dir-
ectly interacts with the P2 promoter region of HDM2,
which is the human homologue of MDM2 (mouse
double minute 2) and inhibits the HDM2 promoterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic model of BCL11B gene isoforms structure (2 splice variants) and protein structure (the location of six zinc fingers).
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interaction between BCL11B and the p300 coactivator at
upstream site 1 (US1) in the IL-2 promoter results in
transcriptional activation of IL-2 expression in activated
T cells [11]. BCL11B enhances TCR/CD28-triggered NF-
κB activation by up-regulating Cot kinase gene expres-
sion in T-cells [12].
T-cell development and the maintenance of T-cell identity
BCL11B plays a key role in both T-cell development and
subsequent maintenance of T-cell identity [13]. BCL11B
is necessary for T lineage commitment in mice, and is
specifically required in order to successfully repress nat-
ural killer cell-associated genes while down-regulating a
battery of stem or progenitor cell genes at their pivotal
commitment stage [6].
BCL11B-deficient mice demonstrate a block at their
CD4-CD8- DN thymocytes development stage without
impairment in any of the cells in the B- and γδ T-cell
lineages. However, Bcl11b−/− thymocytes demonstrated
unsuccessful Vβ to Dβ recombination, and lacked neces-
sary pre-T cell receptor (TCR) complex expression on
the cell surface; this was due to the absence of TCRβ
mRNA expression. Further, the researchers observed
massive apoptosis in the thymi of neonatal BCL11B−/−
mice, results which indicate that BCL11B is a key regula-
tor of the differentiation and survival of αβ T cells
during thymocyte development [14]. Removal of the
BCL11B transcription factor in double positive (DP) thy-
mocytes leads to an early block in invariant natural killer
T-cell (iNKT) development. Remarkably, these studies
demonstrated a unique, previously undescribed role
played by BCL11B in DP thymocytes, in addition to itsalready critical function in the positive selection of con-
ventional CD4 and CD8 single-positive thymocytes [15].
T cells and mature T cells both acquire NK cell proper-
ties, transforming them into natural killer (NK) cells
upon BCL11B deletion during culture. These repro-
grammed cells possess unique properties of proliferation,
cytokine dependency and target cell killing [1,16]. Our
data revealed that after BCL11B up-regulation, naïve T
cells increased their proliferation ability; predominantly
in the Th differentiated subset [17], which may result
from increased CXCL10 and CXCL11 expression. After
BCL11B down-regulation, proliferation capacity substan-
tially decreased, which could be related to changes in ex-
pression of the mitochondrial pathway genes CFLAR,
CASP8, and CASP10. Moreover, we found that BCL11B
was indispensable for Treg suppressor function, the
maintenance of optimal Foxp3 and IL-10 gene expres-
sion, and the induction of Foxp3 expression in conven-
tional CD4+ T cells in response to TGF-β and iTreg cell
generation [18].
Tumor suppressor
BCL11B has recently been identified as a tumor suppres-
sor gene [5,19]. It has been demonstrated that BCL11B
is a haplo-insufficient tumor suppressor which collabo-
rates with all major T-cell, acute lymphoblastic leukemia
(T-ALL) oncogenic lesions during human thymocyte
transformation [19], the loss of a BCL11B allele provides
susceptibility to mouse thymic lymphoma [20] and
human T-ALL [21-23]. The absence of a BCL11B tumor
suppressor resulted in vulnerability to DNA replication
stress and damage [24]. Down-regulation of the BCL11B
gene by small interfering RNA (siRNA) led to growth
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although not in normal mature T and CD34+ cells
[25-27].
BCL11B alterations in hematological malignancies
Deletion/mutation/disruption
The findings indicated that BCL11B haplo-insufficiency
occurred across each of the major T-ALL molecular
subtypes, including the early T-cell precursor, HOXA-
positive, LEF1-inactivated, and TAL1-positive subtypes
[19]. Loss-of-function BCL11B mutations contribute to
mouse lymphomagenesis and thus potentially also to
human cancer development [20]. Monoallelic BCL11B
deletions or missense mutations were found in 9% (10/
117) of a collection of T-ALL diagnostic specimens.
There are at least six examples of intra-chromosomal
interstitial BCL11B deletions caused by aberrant V (D) J
recombination between non-antigen receptor loci, and
five of these six are associated with lymphoid malignancy.
Although the efficiency of these illegitimate V (D) J re-
combination events is less, by several orders of magni-
tude than at bonafide antigen receptor loci, such
deletions result in devastating consequences, and repre-
sent a major cause of lymphoid malignancy [28]. Analysis
of the D-J rearrangement at the TCRβ locus and cell sur-
face markers after the γ-irradiation of BCL11B (KO/+)
mice revealed that BCL11B allelic loss had occurred at
the stage following V(D)J recombination. BCL11B het-
erozygosity can affect lymphomagenesis at the CD117high
DN2 stage which occurs after the CD117high DN1 stage.
In BCL11B (KO/+) thymocytes, the expression of recog-
nized oncogenic protein β-catenin was increased. Subse-
quently, the BCL11B (KO/+) genotype contributes to
clonal expansion and differentiation arrest, which is due
in part to an increase in the β-catenin level [5,29]. Struc-
tural homology modeling revealed that several of the
BCL11B mutations disrupted the structure of zinc finger
domains which are necessary in order for this transcrip-
tion factor to bind DNA.
Rearrangement/juxtaposition
Cytogenetic studies in a patient with acute myeloid
leukemia (AML) revealed that the sole karyotypic al-
teration of a half-cryptic rearrangement, which was
identified as t (6; 14) (q25-q26; q32), involved the
BCL11B gene [30]. A cryptic chromosome rearrange-
ment, t (5;14)(q35.1;q32.2) was recently identified in a
pediatric patient with acute lymphoblastic leukemia
(ALL) [31-34], T/myeloid acute bilineal leukemia [35],
and a pediatric T-ALL cell line (HPB-ALL); the re-
arrangement of which targets activation in HOX11L2/
TLX3 at 5q35.1 through juxtaposition with a down-
stream region of BCL11B at 14q32.2 [36]. A
rearrangement of NKX2-5-BCL11B was also found inT-cell lines PEER and CCRF-CEM, which resulted in
a high level of NKX2-5 expression. NKX2-5 is a
homeodomain-containing transcription factor expressed
in the nucleus during embryonic development, which
has been associated with T-ALL [37].
Overexpression
In the human body, BCL11B over-expression is primarily
found in T-ALL [25,26]. A comparison of genome pro-
files of acute and lymphoma types revealed BCL11B
over-expression in the acute form, regardless of the
14q32 gain/amplification, but either low or no levels of
this gene’s expression in the lymphomas; these results
suggest that acute and lymphoma types are genomically
distinct subtypes, which thus may develop tumors via
distinct genetic pathways [38]. Apoptosis resistance trig-
gered by BCL11B over-expression was found to be ac-
companied by chemo-resistance caused by the
accumulation of T-ALL cells in the G1 phase [39].
Methylation status
Based on a genome-wide analysis of aberrant DNA
methylation in chronic lymphocytic leukemia (CLL)
using methylated CpG island amplification (MCA),
coupled with a promoter microarray, methylation status
was confirmed through pyro-sequencing for 22 of these
genes in 78 CLL patients, including BCL11B[40]. How-
ever, the contribution of inactivation of BCL11B in
B-CLL cells requires further investigation.
Targeted therapies
Based upon funding proposal data, BCL11B targeting
may be considered a new therapeutic strategy for
T-cell malignancies. BCL11B silencing by RNA inter-
ference in T-ALL significantly inhibited cell prolifera-
tion and induced apoptosis. The molecular mechanism
behind this result may be related to several pathways
which mainly include the apoptosis pathway (e.g.,
TNFSF10, BIK, BNIP3, and BCL2L1 genes) and the
TGF beta pathway (e.g., SPP1 and CREBBP genes)
(Figure 2A) [41,42]. Global gene expression profile
analysis revealed that the PHTF1 (putative homeodo-
main transcription factor 1) gene increased 16-fold in
BCL11B siRNA-treated T-ALL cells (Figure 2B). Fur-
ther, proteome analysis verified that in fact new
mechanisms of BCL11B-loss driven apoptosis may be
related to the mitochondrial apoptotic pathway, and
observed cleavage and fragments of known caspase tar-
gets may be involved: such as myosin, spectrin, vimen-
tin, and ERM proteins, which were up-regulated and
phosphorylated upon BCL11B down-regulation. More-
over, the levels of several proteins implicated in cell
cycle entry, including DUT-N, CDK6, MCM4, MCM6,
and MAT1, were elevated [43].
Figure 2 Schematic model of molecular mechanism of BCL11B pathways (A) and differentially expressed genes in BCL11B
siRNA-treated T-ALL cells (B).
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To improve T-cell malignancy treatment strategies, fur-
ther work is necessary in order to most accurately iden-
tify therapeutic targets. Gastrointestinal stromal tumor
(GIST) research and clinical care sets are examples of
such translational research, capable of transforming la-
boratory discoveries into successful clinical applications
[44]. A promising therapeutic target for T-cell malig-
nancy therapy can indeed be the result of this funda-
mental, mechanistic understanding of the role of
BCL11B; its regulation of the apoptotic process, and its
over-expression in leukemic T cells, using a monoclonal
antibody, small molecule inhibitor (or siRNA). It should
be noted, however, that the inhibitory effects may be
limited for single agents, and its combination withchemotherapy may have a distinctly synergistic effect in
killing the leukemic cells.
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